Abstract
Objective: Restenosis after Percutaneous Coronary Intervention (PCI) is regarded as the result of a combination of various pathological events. The mechanisms are complex and not completely understood. This study aims to determine the correlation between the concentration of serum sulfatide and restenosis after PCI. Method: We studied 68 consecutive patients with CHD of single-vessel disease who successfully underwent PCI. All patients were evaluated by a follow-up angiography approximately 6.5 months after the PCI and were divided into two groups, the restenosis (20 patients) and the nonrestenosis (48 patients). We measured and compared serum sulfatide levels and conventional cardiovascular risk factors in those two groups. Result: The serum sulfatide concentration (18.73 ± 3.81 μmol/L) in the restenosis group was significantly higher than that (11.52 ± 3.37 μmol/L) in the nonrestenosis group (p<0.01). Multiple logistic regression analysis for risk factors revealed a significant correlation between serum sulfatide and restenosis after PCI (p<0.05). The concentration of serum sulfatide was positively correlated with the coronary percent stenosis at the time of follow-up angiography (r=0.32, p<0.05). Conclusion: High concentration of serum sulfatide is therefore a risk factor for restenosis after PCI in patients with CHD.
Highlights
Percutaneous Coronary Intervention (PCI) is an established myocardial revascularization procedure
Lots of experimental and clinical studies have shown that serum sulfatide is related to Atherosclerosis (AS) [2,4] and Coronary Heart Disease (CHD), may be a novel biomarker for cardiovascular disease in patients with end-stage renal failure [5]
We examined the relationship between serum sulfatide concentration and restenosis after PCI to investigate whether serum sulfatide is a novel predictor of restenosis after PCI in patients with CHD
Summary
Percutaneous Coronary Intervention (PCI) is an established myocardial revascularization procedure. Restenosis after successful PCI remains a significant problem, which occurs in approximately one-third of patients within 6 months [1]. Restenosis is regarded as the result of a combination of various pathophysiologic events including artery atherosclerosis, inflammatory reaction, thrombogenesis, and the proliferation of vascular components such as the extracellular matrix in an injured vessel [2]. Lots of experimental and clinical studies have shown that serum sulfatide is related to Atherosclerosis (AS) [2,4] and Coronary Heart Disease (CHD), may be a novel biomarker for cardiovascular disease in patients with end-stage renal failure [5]. Serum sulfatide is closely related to inflammatory reaction and thrombogenesis, even the proliferation of the extracellular matrix in an injured vessel [2,4,6]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
